Johnson & Johnson’s (JNJ) Janssen Pharmaceutical Cos. unit on
Wednesday said the European Commission approved the expanded use of
Erleada to treat adult men with metastatic hormone-sensitive prostate
cancer in combination with androgen deprivation therapy.
The drug maker said the approval could benefit a population of more than 100,000 people across Europe.
Erleada was previously approved in Europe for use in adults with
non-metastatic castration-resistant prostate cancer who are at high risk
of developing metastatic disease.
https://www.marketscreener.com/JOHNSON-JOHNSON-4832/news/Johnson-Johnson-J-J-s-Janssen-Gets-Expanded-European-Approval-for-Erleada-29906469/
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.